05-82000-28

Original Effective Date: 10/15/01

Reviewed: 12/05/19

Revised: 07/01/20

Subject: Genetic Testing

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

DESCRIPTION:

A genetic or genomic test involves an analysis of human chromosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or gene products (e.g., enzymes and other types of proteins) to detect heritable or somatic variants, genotypes, or phenotypes related to disease and health.

There are several different types of genetic tests available today, including:

- **Carrier testing:** Carrier testing is used to identify people who carry one copy of a gene mutation that, when present in two copies, causes a genetic disorder. This type of testing is offered to individuals who have a family history of a genetic disorder and to people in certain ethnic groups with an increased risk of specific genetic conditions. If both parents are tested, the test can provide information about a couple's risk of having a child with a genetic condition.
- **Diagnostic testing:** Diagnostic testing is used to identify or rule out a specific genetic or chromosomal condition. In many cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical signs and symptoms. Diagnostic testing can be performed before birth or at any time during a person's life, but is not available for all genes or all genetic conditions.
- **Newborn screening:** Newborn screening is used just after birth to identify genetic disorders that can be treated early in life. Millions of babies are tested each year in the United States. All states currently test infants for phenylketonuria (a genetic disorder that causes intellectual disability if left untreated) and congenital hypothyroidism (a disorder of the thyroid gland). Most states also test for other genetic disorders.
- **Predictive and presymptomatic testing:** Predictive and presymptomatic types of testing are used to detect gene variants associated with disorders that appear after birth, often later in life. These tests can be helpful to people who have a family member with a genetic disorder, but who have no features of the disorder themselves at the time of testing. Predictive testing can identify variants that increase a person's risk of developing disorders with a genetic basis, such as certain types of cancer.

Presymptomatic testing can determine whether a person will develop a genetic disorder before any signs or symptoms appear.

- **Preimplantation testing:** Preimplantation testing, also called preimplantation genetic diagnosis (PGD), is a specialized technique that can reduce the risk of having a child with a particular genetic or chromosomal disorder. It is used to detect genetic changes in embryos that were created using assisted reproductive techniques such as in-vitro fertilization. To perform preimplantation testing, a small number of cells are taken from these embryos and tested for certain genetic changes.
- **Prenatal testing:** Prenatal testing is used to detect changes in a fetus's genes or chromosomes before birth. This type of testing is offered during pregnancy if there is an increased risk that the baby will have a genetic or chromosomal disorder. In some cases, prenatal testing can lessen a couple's uncertainty or help them make decisions about a pregnancy. However, it cannot identify all possible inherited disorders and birth defects.

Cytogenetics is a branch of genetics that is involved with heredity and the cellular components, particularly chromosomes, associated with heredity. Cytogenetic testing involves the determination of chromosome number and structure. Variations in either the chromosome number or structure can produce numerous abnormalities that may lead to cancer, syndromes, or birth defects.

POSITION STATEMENT:

NOTE: Coverage for genetic testing, screening, and counseling are applicable only under those contracts that include benefits for genetic testing, preventive health services, screening services, and medical counseling.

GENETIC TESTING TO ESTABLISH A DIAGNOSIS OF INHERITABLE DISEASE

Genetic testing **meets the definition of medical necessity** when used to establish a molecular diagnosis of an inheritable disease when the following criteria are met:

- The member displays clinical features, or is at direct risk of inheriting the mutation in question (presymptomatic); **AND**
- The result of the test will directly impact the treatment being delivered to the member; **AND**
- After history, physical examination, pedigree analysis, genetic counseling, and completion of conventional diagnostic studies, a definitive diagnosis remains uncertain, and one of the diagnoses listed in the table below may be suspected (the list is not all-inclusive)

  OR

- For assisted reproductive technology (also known as preimplantation genetic testing [PGT] or preimplantation genetic diagnosis [PGD]) cases (i.e. in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), artificial insemination) where either parent is known to have a chromosomal abnormality. Results of testing must impact reproductive treatment and planning. **NOTE:** applicable only under those contracts that include infertility benefits.

Diagnosis Table:

Albinism (albino)	Cystic Fibrosis (CF) **(see criteria below)**	Hemochromatosis (gene sequence analysis)	Retinoblastoma
Angelman Syndrome (see criteria below)	Duchenne Muscular Dystrophy (DMD) or Becker Muscular	Huntington's Chorea (see criteria below)	Sickle Cell Anemia

	Dystrophy (BMD) **(see criteria below)**		
Canavan Disease	Fabry Disease	Myotonic Dystrophy (see criteria below)	Spinal Muscular Atrophy
Chromosome 22q11.2 Deletion Syndrome **(see criteria below)**	Fragile X Syndrome (see criteria below)	Niemann-Pick (enzyme or mutation analysis)	Tuberous Sclerosis (see criteria below)
Charcot-Marie-Tooth Disease	Gaucher Disease (see criteria below)	Prader-Willi Syndrome **(see criteria below)**	Von Hippel-Lindau Syndrome

The following test list includes, but is not limited to, specific indications for testing that may **meet the definition of medical necessity** and those for which testing is considered **experimental or investigational**.

Diagnosis	**Criteria**
Angelman Syndrome	Genetic testing for Angelman Syndrome **meets the definition of medical necessity** for **ONE** of the following: • Cytogenic deletion is suspected on chorionic villus sampling (CVS) or amniocentesis • Previous child diagnosed with Angelman Syndrome caused by a UBE3A mutation.
Chromosomal Microarray Analysis (CMA) (Also referred to as genomic hybridization (CGH) or array comparative genomic hybridization (aCGH).) [1](Anora™ miscarriage test, CombiSNP™ Array for Pregnancy Loss, and CombiBAC™ Array)	Chromosome microarray (CMA) analysis **meets the definition of medical necessity** as an alternative to karyotyping in members who are undergoing invasive diagnostic prenatal (fetal) testing, [1]Chromosomal microarray analysis of fetal tissue **meets the definition of medical necessity** for the evaluation of pregnancy loss in cases of pregnancy loss at 20 weeks of gestation or earlier when there is a maternal history of recurrent miscarriage (defined as a history of 2 or more failed pregnancies); or in all cases of pregnancy loss after 20 weeks of gestation. Chromosomal microarray analysis of fetal tissue in cases of miscarriage or intrauterine fetal demise is considered **experimental or investigational** in all other situations. There is insufficient clinical evidence to permit conclusions on net health outcomes. The use of next generation sequencing in the setting of invasive prenatal testing is considered **experimental or**

	investigational. There is a lack of clinical data to permit conclusions on efficacy and net health outcomes.
Chromosome 22q11.2 Deletion Syndrome	Genetic testing for chromosome 22q11.2 deletion syndrome **meets the definition of medical necessity** in an at-risk fetus based on ultrasound findings or family history.
Cystic Fibrosis (CF)	Genetic carrier testing for cystic fibrosis **meets the definition of medical necessity** for **ONE** of the following: • Individuals with a positive family history of CF • Either parent has a diagnosis of CF • Fetal echogenic bowel has been identified on ultrasound • Couples currently planning a pregnancy or seeking prenatal testing.
Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD)	Genetic testing for DMD gene variants **meets the definition of medical necessity** for the following conditions: • In a male with signs and symptoms of a dystrophinopathy in order to confirm the diagnosis and direct treatment. • For at-risk female* relatives: o To confirm or exclude the need for cardiac surveillance o For preconception testing to determine the likelihood of an affected offspring in a woman considering a pregnancy. • For at-risk male** offspring to confirm or exclude the need for medical and cardiac surveillance. *(At-risk female: first- and second-degree female relatives and include the proband's mother, female siblings of the proband, female offspring of the proband, the proband's maternal grandmother, maternal aunts, and their offspring). **(At-risk male: an asymptomatic male offspring of a female carrier or an asymptomatic male sibling of a patient with a DMD-associated dystrophinopathy). Genetic testing for DMD gene variants is considered **experimental or investigational** in all other situations. There is a lack of clinical data to permit conclusions on health outcomes.
Fetal RHD	Noninvasive fetal RHD genotyping using cell-free fetal DNA is considered **experimental or investigational**. It is uncertain

(SensiGene™ Fetal RHD)	whether this testing will lead to improved health outcomes and the evidence is insufficient to determine the effects of the technology on health outcomes.
FMR1 Variants (Including Fragile X Syndrome)	See below.
Gaucher Disease	Genetic testing for Gaucher Disease **meets the definition of medical necessity** for **ONE** of the following: • There is an affected family member who has an identified GBA mutation or Gaucher disease • Either parents or a previously affected sibling have an identified GBA mutation or Gaucher disease.
Huntington's Chorea	Genetic testing for Huntington's chorea **meets the definition of medical necessity** when there is a confirmed diagnosis of Huntington's chorea in the family.
Myotonic Dystrophy	Genetic testing for myotonic dystrophy (Types 1 or 2) **meets the definition of medical necessity** for **ONE** of the following: • At least one parent has a confirmed diagnosis of myotonic dystrophy • At least one parent has been diagnosed as a presymptomatic carrier of myotonic dystrophy.
Prader-Willi Syndrome	Genetic testing for Prader-Willi Syndrome **meets the definition of medical necessity** when **ONE** of the following: • Previous child diagnosed with Prader-Willi Syndrome • Cytogenic deletion is suspected on chorionic villus sampling (CVS) or amniocentesis.
Single-Gene Disorders	Invasive diagnostic prenatal (fetal) testing for molecular analysis for single-gene disorders **meets the definition of medical necessity** when a pregnancy has been identified as being at high risk for: 1. Autosomal dominant conditions, at least 1 of the parents has a known pathogenic variant. 2. Autosomal recessive conditions: • Both parents are suspected to be carriers or are known to be carriers, **OR** • One parent is clinically affected and the other parent is suspected to be or is a known carrier. 3. X-linked conditions: A parent is suspected to be or is a

	known carrier. **AND ALL** of the following are met: • The natural history of the disease is well understood, and there is a reasonable likelihood that the disease is one with high morbidity in the homozygous or compound heterozygous state • Any variants have a high penetrance • The genetic test has adequate sensitivity and specificity to guide clinical decision making and residual risk is understood, **AND** • An association of the marker with the disorder has been established. Invasive diagnostic prenatal (fetal) testing for molecular analysis for single-gene disorders is considered **experimental or investigational** if the above criteria are not met. There is insufficient clinical evidence to permit conclusions on net health outcomes.
Tuberous Sclerosis	Genetic testing for Tuberous Sclerosis **meets the definition of medical necessity** for **ONE** of the following: • Family history of Tuberous Sclerosis • A specific mutation in the TSC1 and TSC2 gene has been identified in an affected family member.
Whole Exome Sequencing **Whole Genome Sequencing**	See below.

For all other indications not listed above genetic testing for prenatal screening is considered **experimental or investigational**. This includes testing for the general population including genetic disease screening panels, as well as large comprehensive carrier screening panels (e.g. Counsyl Universal Carrier Genetic test, GoodStart Select, InheriGen™, Inheritest™, Natera One™ Disease Panel, Natera Horizon). There is a lack of clinical data to permit conclusions on net health outcomes.

Genetic testing of children to predict adult onset diseases **does not meet the definition of medical necessity** unless test results will guide current decisions concerning prevention and this benefit would be lost by waiting until the child has reached adulthood.

NEWBORN SCREENING

See U.S. Preventive Services Task Force (USPSTF) Recommendations at uspreventiveservicestaskforce.org.

POSTNATAL AND OTHER GENETIC TESTS

NOTE: Coverage for genetic testing, screening, and counseling are applicable only under those contracts that include benefits for genetic testing, preventive health services, screening services, and medical counseling.

To be considered genetic testing (vs. genetic screening) for indications other than to establish a diagnosis of inheritable disease, **ALL** of the following criteria must be met:

Diagnostic results from conventional testing and physical examination are inconclusive; **AND**

Results of molecular diagnostic testing are necessary to guide treatment decisions.

The following test list includes, but is not limited to, specific indications for testing that may **meet the definition of medical necessity** and those for which testing is considered **experimental or investigational**.

TEST	CRITERIA
5-Fluorouracil (5-FU) (My5-FU™; TheraGuide®)	My5-FU™ assay testing or other types of assays for determining 5-fluorouracil (5-FU) area under the curve in order to adjust 5-FU dose for members with colorectal cancer or other cancers is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes. Testing for genetic variants in dipyrimidine dehydrogenase (DPYD) or thymidylate synthase (TYMS) genes to guide 5-FU dosing and/or treatment choice in members with cancer is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.
Cytogenetically Normal Acute Myeloid Leukemia	Genetic testing for FLT3 internal tandem duplication (FLT3-ITD), NPM1, and CEBPA variants **meets the definition of medical necessity** in cytogenetically normal acute myeloid leukemia when testing will be used to guide management decisions in members who would receive treatment other than low-dose chemotherapy or best supportive care. Genetic testing for FLT3 internal tandem duplication (FLT3-ITD), NPM1, and CEBPA variants is considered **experimental or investigational** in all other situations. The evidence is insufficient to determine the effects of the technology on health outcomes. Genetic testing for FLT3 tyrosine kinase domain variants is considered **experimental or investigational** for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes. Genetic testing for FLT3, NPM1, and CEBPA variants to

	detect minimal residual disease is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.
Alzheimer Disease **Note:** Genetic testing for Alzheimer disease may be offered along with analysis of cerebral spinal fluid levels of the tau protein and amyloid-b peptide 1-42 (see MCG 05-86000-22). This group of tests may be collectively referred to as the ADmark™ Profile, offered by Athena Diagnostics.	Targeted genetic testing for a known familial variant in the presenilin genes (PSEN) or amyloid-beta precursor protein (APP) gene associated with autosomal dominant early-onset Alzheimer disease **meets the definition of medical necessity** in an asymptomatic member to determine future risk of disease when the following criteria are met: • The member has a close relative (ie, first- or second-degree relative) with a known familial variant associated with autosomal dominant early-onset Alzheimer disease **AND** • Results of testing will inform reproductive decision making. Genetic testing for variants in presenilin genes (PSEN) or amyloid-beta precursor protein (APP) gene associated with autosomal dominant early-onset Alzheimer disease **meets the definition of medical necessity** in an asymptomatic member to determine future risk of disease when the following criteria are met: • The member has a family history of dementia consistent with autosomal dominant Alzheimer disease for whom the genetic status of the affected family members is unavailable AND • Results of testing will inform reproductive decision making. Genetic testing for the risk assessment of Alzheimer disease in asymptomatic members is considered **experimental or investigational** in all other situations. Genetic testing includes, but is not limited to, testing for the apolipoprotein E ε4 allele (APOE) or triggering receptor expressed on myeloid cells 2 (TREM2). There is insufficient clinical evidence to permit conclusions on health outcomes.
Assessment of Measurable Residual Disease (MRD)	Next-generation sequencing to detect MRD (eg. ClonoSEQ®) at a threshold of 10^{-4} as an alternative test in members with acute lymphoblastic leukemia or multiple myeloma **meets the definition of medical necessity**. Next-generation sequencing to detect MRD at a threshold of *less* than 10^{-4} in members with acute lymphoblastic leukemia or multiple myeloma is considered **experimental or investigational**. The evidence is insufficient to determine the

	effects of the technology on health outcomes. Next-generation sequencing to detect MRD in all other situations is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.
α-Thalassemia	Preconception (carrier) testing for α-thalassemia in prospective parents **meets the definition of medical necessity** when both parents have evidence of possible α-thalassemia (including α-thalassemia minor, hemoglobin H disease [α-thalassemia intermedia], or α-thalassemia major) based on biochemical testing. Genetic testing to confirm a diagnosis of α-thalassemia **does not meet the definition of medical necessity**. The diagnosis of α-thalassemia can be made without genetic testing. Genetic testing of members with hemoglobin H disease (α-thalassemia intermedia) to determine prognosis is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on health outcomes. Genetic testing for α-thalassemia in other clinical situations is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on health outcomes. (Prenatal testing is not addressed in the position statements above.)
Biallelic RPE65 Inherited Retinal Dystrophies	Genetic testing to detect the presence of pathogenic variants in the RPE65 gene **meets the definition of medical necessity** to establish a diagnosis of inherited retinal dystrophy.
Cancer Susceptibility Panels (BRCAplus, BreastNext™, BreastSentry, BROCA Cancer Risk Panel, CancerNext™, ColoNext™, Color, ColoSeq™, Comprehnsive Cancer Panel, Counsyl Reliant Cancer Screen,GYNPlus, High/Moderate Risk Panel, MSK-IMPACT, myRisk™ NGS, OvaNext™, ProstateNext, TumorNext)	Genetic cancer susceptibility panel testing is considered **experimental or investigational**. There is a lack of clinical data to permit conclusions on clinical utility and net health outcomes.

CADASIL Syndrome

Genetic testing for a NOTCH3 variant to confirm the diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) syndrome in a member **meets the definition of medical necessity** under the following conditions:

- Clinical signs, symptoms, and imaging results are consistent with CADASIL, indicating that the pretest probability of CADSIL is at least in the moderate-to-high range (score of 14 or greater*); **AND**
- The diagnosis of CADASIL is inconclusive following alternative methods of testing, including magnetic resonance imaging.

For individuals who are asymptomatic with a family member with a diagnosis of CADASIL syndrome:

- If there is a family member (first- and second-degree relative) with a known variant, targeted genetic testing of the known NOTCH3 familial variant **meets the definition of medical necessity.**
- If the family member's genetic status is unknown, genetic testing of NOTCH3 **meets the definition of medical necessity.**

Genetic testing for a NOTCH3 variant to confirm the diagnosis of CADASIL syndrome in all other situations is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on health outcomes.

***Screening Tool to Select Patients for NOTCH3 Gene:**

Features	No. With NOTCH3 Variant	Percent With NOTCH3 Variant	Points
Clinical:			
Migraine	239/463	52%	1
Migraine with aura	65/85	76%	3
Transient ischemic attack/stroke	380/526	72%	1 (2 if <50 y)
Psychiatric disturbance	106/380	28%	1
Cognitive decline	188/434	43%	3
Radiologic:			
LE	277/277	100%	3
LE extended	174/235	74%	1

	to temporal pole			
	LE extended to external capsule	228/303	75%	5
	Subcortical infarcts	210/254	83%	2

Cardiovascular Disease or Aneurysm (9p21-EarlyMICheck™ Genotype Test, deCODE MI™)	The use of genotyping for 9p21 single nucleotide polymorphisms is considered **experimental or investigational**, including but not limited to, identification of members who may be at increased risk of cardiovascular disease or its manifestations (e.g., MI, ischemic stroke, peripheral arterial disease, coronary artery calcification), or identification of members who may be at increased risk for aneurysmal disease (abdominal aortic aneurysms, intracranial aneurysms, polypoidal choroidal vasculopathy). There is insufficient evidence regarding the clinical utility of this testing to permit conclusions on health outcomes.
Cardiovascular Risk and/or Effectiveness of Statin Therapy (Cardio IQ™ KIF6 Genotype, KIF6 StatinCheck™ Genotype)	KIF6 Genotyping is considered **experimental or investigational** for predicting cardiovascular risk and/or the effectiveness of statin therapy. There is insufficient evidence on the clinical validity of the testing to permit conclusions on health outcomes.
Celiac Disease (HLA Typing; PROMETHEUS® Celiac PLUS)	HLA-DQ2 and HLA-DQ8 testing **meets the definition of medical necessity** to rule out celiac disease in individuals with discordant serologic and histologic (biopsy) findings or if persistent symptoms warrant testing despite negative serology and histology. HLA-DQ2 and HLA-DQ8 testing for celiac disease is considered **experimental or investigational** in all other situations. There is insufficient clinical evidence to permit conclusions on net health outcomes.
Chromosomal Microarray Analysis (CMA) (Also referred to as genomic hybridization (CGH) or array comparative genomic hybridization (aCGH).)	Chromosomal microarray analysis **meets the definition of medical necessity** as first line testing in the initial postnatal evaluation of members with any of the following: • Apparent nonsyndromic developmental delay/intellectual disability • Autism spectrum disorder **OR** • Multiple congenital anomalies not specific to a well-delineated genetic syndrome.

(Affymetrix CytoScan® Dx; FirstStepDx PLUS; Reveal® SNP Microarray Pediatric)	Chromosomal microarray analysis is considered **experimental or investigational** for the evaluation of all other conditions of delayed development, including but not limited to idiopathic growth or language delay. The evidence is insufficient to determine the effects of the technology on health outcomes. Panel testing using next-generation sequencing (NGS) is considered **experimental or investigational** in all cases of suspected genetic abnormality in children with developmental delay/intellectual disability, autism spectrum disorder or congenital anomalies. The evidence is insufficient to permit conclusions whether NGS panel testing improves outcomes.
Cardiac Ion Channelopathies [Includes QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome (BrS), and short QT syndrome (SQTS)] (FAMILION® Test)	**Long QT Syndrome (LQTS)** Genetic testing to confirm a diagnosis of congenital LQTS **meets the definition of medical necessity** when signs and/or symptoms of LQTS are present but a definitive diagnosis cannot be made without genetic testing. This includes: • Members who do not meet the clinical criteria for LQTS (i.e., those with a Schwartz score less than 4), but who have a moderate-to-high pretest probability based on the Schwartz score and/or clinical criteria. Note: Determining the pretest probability of LQTS is not standardized. An example of a member with a moderate-to-high pretest probability of LQTS is a member with a Schwartz score of 2 – 3. Refer to Diagnostic Scoring System* for LQTS below. Genetic testing of asymptomatic members to determine future risk of LQTS **meets the definition of medical necessity** when at least one of the following criteria is met: • A close relative (ie, first-, second-, or third-degree relative) with a known LQTS mutation; **OR** • A close relative diagnosed with LQTS by clinical means whose genetic status is unavailable. Genetic testing for LQTS for all other situations not meeting criteria above, including but not limited to determining prognosis and/or directing therapy in members with known LQTS is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on net health outcomes. **Catecholaminergic Polymorphic Ventricular Tachycardia**

	(CPVT) Genetic testing to confirm a diagnosis of CPVT **meets the definition of medical necessity** when signs and/or symptoms of CPVT are present, but a definitive diagnosis cannot be made without genetic testing. Genetic testing of asymptomatic members to determine future risk of CPVT **meets the definition of medical necessity** when at least one of the following criteria is met: • A close relative (ie, first-, second-, or third-degree relative) with a known CPVT mutation; **OR** • A close relative diagnosed with CPVT by clinical means whose genetic status is unavailable. Genetic testing for CPVT for all other situations not meeting the criteria above is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on net health outcomes. **Brugada Syndrome (BrS)** Genetic testing to confirm a diagnosis of BrS **meets the definition of medical necessity** when signs and/or symptoms consistent with BrS are present but a definitive diagnosis cannot be made without genetic testing. Genetic testing of asymptomatic members to determine future risk of BrS **meets the definition of medical necessity** when members have a close relative (ie, first-, second-, or third-degree relative) with a known BrS mutation. Genetic testing for BrS for all other situations not meeting the criteria above is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on net health outcomes. **Short QT Syndrome (SQTS)** Genetic testing of asymptomatic members to determine future risk of SQTS **meets the definition of medical necessity** when members have a close relative (ie, first-, second-, or third-degree relative) with a known SQTS mutation. Genetic testing for SQTS for all other situations not meeting the criteria above is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on net health outcomes. **NOTE**: First-degree relatives: children, brothers, sisters and

	parents. Second-degree relatives: grandparents, aunts, uncles, nieces, nephews, half-siblings, and grandchildren. Third-degree relatives: great-grandparents, great-aunts, great-uncles, great-grandchildren, and first cousins.
CHARGE Syndrome	Genetic testing for CHARGE syndrome **meets the definition of medical necessity** to confirm a diagnosis in a member with signs/symptoms of CHARGE syndrome when a definitive diagnosis cannot be made with clinical criteria. Genetic testing for CHARGE syndrome is considered **experimental or investigational** in all other situations. The evidence is insufficient to determine the effects of the technology on health outcomes.
Evaluation of Stable Ischemic Heart Disease	Gene expression testing in the evaluation of members with stable ischemic heart disease is considered **experimental or investigational** for all indications, including but not limited to prediction of coronary artery disease in stable, nondiabetic members. There is a lack of clinical data to permit conclusions on net health outcomes.
Cutaneous Malignant Melanoma (Melaris®)	Genetic testing for genes associated with familial cutaneous malignant melanoma or associated with susceptibility to cutaneous malignant melanoma is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.
Cytochrome P450 Genotype-Guided Treatment Strategy	CYP2D6 genotyping to determine drug metabolizer status **meets the definition of medical necessity** for members with: • Gaucher disease being considered for treatment with eliglustat; **OR** • Huntington disease being considered for treatment with tetrabenazine in a dosage greater than 50 mg per day. CYP450 genotyping for the purpose of aiding in the choice of drug or dose to increase efficacy and/or avoid toxicity for the following drugs is considered **experimental or investigational**: • selection or dosage of codeine • dosing of efavirenz and other antiretroviral therapies for HIV infection • dosing of immunosuppressants for organ

	transplantation • selection or dosing of β-blockers (eg, metoprolol) • dosing and management of antitubercular medications. The evidence is insufficient to determine the effects of the technology on health outcomes. CYP450 genotyping for the purpose of aiding in the choice of clopidogrel vs alternative antiplatelet agents, or in decisions on the optimal dosing for clopidogrel, is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes. The use of genetic testing panels that include multiple CYP450 variants is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.
Dilated Cardiomyopathy	Comprehensive genetic testing for members with signs or symptoms of dilated cardiomyopathy (ie, heart failure or arrhythmias, frequently presenting as dyspnea on exertion and peripheral edema) which is considered idiopathic after a negative workup for secondary causes **meets the definition of medical necessity**. Targeted genetic testing for asymptomatic members with a first-degree relative* who has dilated cardiomyopathy and a known familial variant **meets the definition of medical necessity**. *First-degree relative- child, brother, sister, parent. Genetic testing for dilated cardiomyopathy is considered **experimental or investigational** in all other situations. The evidence is insufficient to determine the effects of the technology on health outcomes.
Duchenne and Becker Muscular Dystrophy	Genetic testing for DMD gene **meets the definition of medical necessity** for the following conditions: • In a male with signs and symptoms of a dystrophinopathy in order to confirm the diagnosis and direct treatment. • For at-risk female relatives (first- and second-degree

	female relatives to include the proband's mother, female siblings of the proband, female offspring of the proband, the proband's maternal grandmother, maternal aunts, and their offspring): • To confirm or exclude the need for cardiac surveillance • For preconception testing to determine the likelihood of an affected offspring in a woman considering a pregnancy. • For at-risk male offspring (asymptomatic male offspring of a female carrier or an asymptomatic male sibling of a member with a DMD-associated dystrophinopathy) to confirm or exclude the need for medical and cardiac surveillance. Genetic testing for DMD gene variants is considered **experimental or investigational** in all other postnatal situations. There is a lack of clinical data to permit conclusions on health outcomes.
FMR1 Variants (Including Fragile X Syndrome)	Genetic testing for FMR1 variants **meets the definition of medical necessity** for the following member populations: Members who have a personal or family history of fragile X syndrome who are seeking reproductive counseling, including: • Prenatal testing of fetuses of known carrier mothers; • Affected members or relatives of affected members who have had a positive cytogenetic fragile X test result who are seeking information on carrier status; • Members who have a family history of fragile X syndrome or a family history of undiagnosed intellectual disability. Members with characteristics of fragile X syndrome or a fragile X−associated disorder, including: • Member with intellectual disability, developmental delay, or autism spectrum disorder; • Members with neurologic symptoms consistent with fragile X-associated tremor or ataxia syndrome; • Women with primary ovarian insufficiency under the age of 40 in whom fragile X-associated primary ovarian insufficiency is suspected. Genetic testing for FMR1 variants is considered **experimental or investigational** for all other uses. The evidence is insufficient to determine the effects of the technology on health outcomes.
Hereditary Pancreatitis	Genetic testing for hereditary pancreatitis **meets the definition of medical necessity** for members aged 18 years

	and younger with unexplained acute recurrent (greater than 1 episode) or chronic pancreatitis with documented elevated amylase or lipase levels. Genetic testing for hereditary pancreatitis is considered **experiemental or investigational** in all other situations. The evidence is insufficient to determine the effects of the technology on health outcomes.
Germline Variants of the RET Proto-Oncogene in Medullary Carcinoma of the Thyroid	Genetic testing for RET proto-oncogene point variants **meets the definition of medical necessity** for the following indications: • Asymptomatic members of families with defined RET gene variants • Members of families known to be affected by inherited medullary thyroid cancer, but not previously evaluated for RET variants • Members with sporadic medullary thyroid cancer. Genetic testing for RET proto-oncogene point variants is considered **experimental or investigational**, as there is insufficient clinical evidence to support the use of genetic testing for screening the general population. There is a lack of clinical data to permit conclusions on efficacy and net health outcomes.

Mental Health Conditions
 	
(GeneSightRX®, PROOVE Drug Metabolism Profile, PHARMAchip, SureGene, MD Tox Expanded Comprehensive Profile; MD Tox Psychiatry & Risk Factors Profile; IDgenetix panels.)
	Genetic testing for diagnosis and management of mental health disorders is considered **experimental or investigational** in all situations, including but not limited to:
	
	• To confirm a diagnosis of a mental health disorder in an individual with symptoms.
	• To predict future risk of a mental health disorder in an asymptomatic individual.
	• To inform the selection or dose of medications used to treat mental health disorders, including but not limited to the following medications:
	  ○ selective serotonin reuptake inhibitors
	  ○ selective norepinephrine reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors
	  ○ tricyclic antidepressants
	  ○ antipsychotic drugs.
	
	The evidence is insufficient to determine the effects of the technology on health outcomes.
	
	Genetic testing panels for mental health disorders, including

	but not limited to the Genecept Assay, STA^{2}R test, the GeneSight Psychotropic panel, the Proove Opioid Risk assay, and the Mental Health DNA Insight panel, are considered **experimental or investigational** for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.
Helicobacter pylori (H. pylori) Treatment (AmHPR H. pylori AB Resistance NGS Panel)	Genotyping to determine cytochrome p450 (CYP2C19) genetic polymorphisms is considered **experimental or investigational** for the purpose of managing the treatment of H. pylori infection. The evidence is insufficient to determine the effects of the technology on health outcomes.
Hereditary Cardiomyopathies	Genetic testing for predisposition to hypertrophic cardiomyopathy (HCM) **meets the definition of medical necessity** for individuals who are at risk for development of HCM, defined as having a first-degree relative with established HCM, when there is a known pathogenic gene variant present in that affected relative. Genetic testing for predisposition to HCM **does not meet the definition of medical necessity** for members with a family history of HCM in which a first-degree relative with established HCM has tested negative for pathogenic variants. Genetic testing for predisposition to HCM is considered **experimental or investigational** for all other member populations, including but not limited to individuals who have a first-degree relative with clinical HCM, but in whom genetic testing is unavailable. The evidence is insufficient to determine the effects of the technology on health outcomes. * (**First-degree relatives**: children, brothers, sisters and parents.) Genetic testing to determine the diagnosis or management of all other hereditary cardiomyopathies, including but not limited to, arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), restrictive, and left ventricular noncompaction cardiomyopathies, is considered **experimental or investigational**. There is a lack of clinical data to permit conclusions on net health outcomes.
Inherited Peripheral Neuropathy	Genetic testing **meets the definition of medical necessity** when the diagnosis of an inherited peripheral motor or sensory neuropathy is suspected due to signs and/or symptoms but a definitive diagnosis cannot be made without

	genetic testing. Genetic testing for an inherited peripheral neuropathy is considered **experimental or investigational** for all other indications. The evidence is insufficient to determine the effects of the technology on health outcomes.
Inherited Thrombophilia	Genetic testing for inherited thrombophilia, including testing for factor V Leiden variant, prothrombin gene variants, and variants in the MTHFR gene, is considered **experimental or investigational**. There is a lack of clinical data to permit conclusions on clinical utility and net health outcomes.
Inflammatory Bowel Disease (Prometheus© IBD sgi Diagnostic™; Prometheus© Crohn's Prognostic; Prometheus© IBD Serology 7)	Determination of anti-neutrophil cytoplasmic antibody (ANCA), anti-Saccharomyces cerevisiae antibody (ASCA), OmpC antibodies, and I2 antibodies is considered **experimental or investigational** as there is insufficient clinical evidence to support the use of determination of ANCA, ASCA, OmpC antibodies, and I2 antibodies in the work-up and monitoring of members with inflammatory bowel disease. There is insufficient evidence to support conclusions regarding effects of ANCA, ASCA, OmpC, and I2 antibodies on health outcomes.
Lactase Insufficiency (LactoType®)	The use of targeted MCM6 -13910C>T variant analysis for the prediction of lactase insufficiency is considered **experimental or investigational**. There is insufficient evidence that the testing would affect medical management or improve clinical outcomes.
Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment (LPA-Aspirin Genetype)	The use of genetic testing for the LPArs3798220 allele (LPA-Aspirin Genotype) is considered **experimental or investigational** in members who are being considered for treatment with aspirin to reduce risk of cardiovascular events. There is insufficient evidence to permit conclusions on how this testing would change medical management and improve health outcomes.
Macular Degeneration (Macula Risk®; Macula Risk®PGx; Vita Risk®)	Genetic testing for macular degeneration is considered **experimental or investigational** for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.
Neurofibromatosis (NF)	Genetic testing for neurofibromatosis **meets the definition of medical necessity** when the diagnosis is clinically suspected due to signs of disease, but a definitive diagnosis cannot be

	made without genetic testing. Genetic testing for neurofibromatosis in at-risk relatives with no signs of disease **meets the definition of medical necessity** when a definitive diagnosis cannot be made without genetic testing **AND** at least one of the following criteria is met: • A close relative (ie, first-, second-, or third-degree relative) has a known NF variant; **or** • A close relative has been diagnosed with neurofibromatosis but whose genetic status is unavailable. Genetic testing for neurofibromatosis for all other situations not meeting the criteria outlined above is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.
Nonfamilial Breast Cancer (BREVAGenplus®, City of Hope Breast Cancer Susceptibility Assay, deCODE BreastCancer™, & deCODEme Complete Scan,)	Testing for one or more single nucleotide variants to predict an individual's risk of breast cancer is considered **experimental or investigational**. The BREVAGenplus breast cancer risk test is considered **experimental or investigational** for all indications, including but not limited to use as a method of estimating individual member risk for developing breast cancer. The evidence is insufficient to determine the effects of the technology on health outcomes.
Pain Management (GeneSight Analgesic; IDgenetix Pain; MD Tox Comprehensive Profile; MD Tox Comprehensive & Risk Factors Profile; MD Tox Pain Profile; Pain Management Panel; PersonaGene Genetic; Proove® Narcotic Risk; Proove® Opioid Risk; Proove® Pain Perception; Pain Medication DNA Insight™; Millennium PGT℠; YouScript®.)	Genetic testing for pain management is considered **experimental or investigational** for all indications. The clinical utility of pharmacogenetic testing in pain management is poorly defined to permit conclusions on health outcomes.
PALB2, CHEK2 and ATM Variants	Testing for PALB2 variants for breast cancer risk assessment **meets the definition of medical necessity** when the

	following criteria (A & B) are met: **A.** The member has undergone testing for sequence variants in BRCA1 and BRCA2 with negative results **AND** **B.** The member meets **one** of the following NCCN™ criteria for genetic risk evaluation: National Comprehensive Cancer Network™ (NCCN™) Criteria for Genetic Risk Evaluation93 1. An individual at any age with a known pathogenic/likely pathogenic variant in a cancer susceptibility gene within the family (irrespective of degree of relatedness), including such variants found on research testing. 2. An individual at any age with a known pathogenic/likely pathogenic variant in a cancer susceptibility gene found on tumor testing. 3. An individual diagnosed at any age with any of the following: Ovarian cancer (includes fallopian tube and primary peritoneal cancers) Pancreatic cancer Metastatic prostate cancer (biopsy-proven and/or with radiographic evidence & includes distant metastasis and regional bed or nodes; not a biochemical recurrence) Breast cancer or high-grade (Gleason score≥7) prostate cancer and of Ashkenazi Jewish ancestry. 4. An individual with a breast cancer diagnosis meeting any of the following: Breast cancer diagnosed age ≤50 years Triple negative (ER-, PR-, HER2-) breast cancer diagnosed age ≤60 years Two breast cancer primaries (includes bilateral (contralateral) disease or two or more clearly separate ipsilateral primary tumors diagnosed either synchronously or asynchronously) Breast cancer at any age and A or B: ≥1 close blood (includes first, second, & third-degree) relative with:

	breast cancer age ≤50 years; or invasive ovarian cancer (includes fallopian tube and primary peritoneal cancers); or male breast cancer; or pancreatic cancer; or high-grade (Gleason score ≥7) or metastatic prostate cancer (biopsy-proven and/or with radiographic evidence & includes distant metastasis and regional bed or nodes; not a biochemical recurrence). ≥2 close blood (includes first, second, & third-degree) relatives with breast cancer at any age. 5. An individual who does not meet the above criteria but has a first- or second-degree relative with any of the following (when possible, genetic testing should be performed first on an affected family member): Breast cancer age ≤ 45 years Ovarian cancer (irrespective of degree of relatedness) Male breast cancer Pancreatic cancer Metastatic prostate cancer (biopsy-proven and/or with radiographic evidence & includes distant metastasis and regional bed or nodes; not a biochemical recurrence) ≥2 breast cancer primaries in a single individual ≥2 individuals with breast cancer primaries on the same side of family with at least one diagnosed age ≤50 years. 6. An individual with a personal and/or family history on the same side of the family of three or more of the following [especially if diagnosed age ≤ 50 years; can include multiple primary cancers in same individual] (when possible, genetic testing should be performed first on an affected family member): breast cancer, sarcoma, adrenocortical carcinoma, brain tumor, leukemia,colon cancer, endometrial cancer, thyroid cancer, kidney cancer, dermatologic manifestations, macrocephaly, hamartomatous polyps of gastrointestinal (GI) tract, lobular breast cancer, difuse gastric cancer, gastrointestinal cancer, hamartomatous polyps, childhood skin pigmentation, ovarian sex chord tumors, pancreatic

	cancer, testicular sertoli cell tumors. (First-degree relatives: parents, siblings, & children; second-degree relatives: grandparents, aunts, uncles, nieces, nephews, grandchildren, & half-siblings; third-degree relatives: great-grandparents, great-aunts, great-uncles, great-grandchildren, first cousins, & half aunts and uncles.) Testing for CHEK2 and/or ATM variants in the assessment of breast cancer risk is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.
Prostate Cancer [1] (Decipher®; Ki-67, Oncotype Dx® Prostate, Oncotype DX® AR-V7	The following genetic and protein biomarkers for the diagnosis of prostate cancer are considered **experimental or investigational:** • Autoantibodies ARF 6, NKX3-1, 5'-UTR-BMI1, CEP 164, 3'-UTR-Ropporin, Desmocollin, AURKAIP-1, CSNK2A2 (eg, Apinify®) • Candidate gene panels • Gene hypermethylation testing (e.g., ConfirmMDx®) • HOXC6 and DLX1 testing (e.g., Select MDx®) • Kallikrein markers (e.g.,4Kscore™ Test) • Mitochondrial DNA variant testing (e.g., Prostate Core Mitomics Test™) • PCA3, ERG, and SPDEF RNA expression in exosomes (e.g., ExoDx™ Prostate IntelliScore) • PCA3 testing (e.g. Progensa®) • Prostate Health Index (phi) • TMPRSS:ERG fusion genes (e.g., Mi-Prostate Score/MiPS). The evidence is insufficient to determine the effects of the technology on health outcomes. Single nucleotide variant testing (e.g., 23and me, deCODE) for cancer risk assessment of prostate cancer is considered **experimental or investigational**.The evidence is insufficient to determine the effects of the technology on health outcomes. [1] Use of gene expression analysis and protein biomarkers to

Nuclear Detect; Prolaris®, PTEN, ProMark™)	guide management of prostate cancer is considered **experimental or investigational** for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.
PTEN Hamartoma Tumor Syndrome (PHTS)	Genetic testing for PTEN **meets the definition of medical necessity** to confirm the diagnosis when a member has clinical signs of a PTEN hamartoma tumor syndrome. Targeted genetic testing for a PTEN familial variant **meets the definition of medical necessity** in a first-degree relative of a proband with a known PTEN pathogenic variant. Genetic testing for PTEN is considered **experiemental or investigational** for all other indications. The evidence is insufficient to determine the effects of the technology on health outcomes.
Rett Syndrome	Genetic testing for Rett syndrome associated genes (eg, MECP2, FOXG1, or CDKL5) **meets the definition of medical necessity** to confirm a diagnosis of Rett syndrome in a child with developmental delay and signs/symptoms of Rett syndrome when a definitive diagnosis cannot be made without genetic testing or to determine carrier status of a mother or a sister of a member with Rett syndrome. All other indications for genetic testing for Rett syndrome associated genes, including routine carrier testing (prenatal or preconception) in members with negative family history, and testing of asymptomatic family members to determine future risk of disease, are considered **experimental or investigational**. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
ScoliScore™	DNA-based prognostic testing for adolescent idiopathic scoliosis is considered **experimental or investigational**. There is insufficient clinical evidence in peer-reviewed literature to permit conclusions on net health outcomes.
Statin-Induced Myopathy (Statin Induced Myopathy (SLCO1B1) Genotype, SLCO1B1 Variants)	Genetic testing for the presence of variants in the SLCO1B1 gene for the purpose of identifying members at risk of statin-induced myopathy is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on health outcomes.
Tamoxifen Treatment	Genotyping to determine cytochrome p450 (CYP2D6) genetic

	variants is considered **experimental or investigational** for the purpose of managing treatment with tamoxifen for women at high risk for or with breast cancer. The evidence is insufficient to determine the effects of the technology on health outcomes.
Warfarin Dosing (eQ-PCR™ LightCycle; eSensor® Warfarin Plus; eSensor® Warfarin Sensitivity; INFINITI 2C9-VKORC1 Multiplex Assay; Rapid Genotyping Assay; Verigence Warfarin Metabolism Nucleic Acid Test®)	Genotyping to determine cytochrome p450 2C9 (CYP2C9), P450 4F2 (CYP4F2), and vitamin K epoxide reductase subunit C1 (VKORC1) genetic variants is considered **experimental or investigational** for the purpose of managing the administration and dosing of warfarin, including use in guiding the initial warfarin dose to decrease time to stable INR and reduce the risk of serious bleeding. The evidence is insufficient to determine the effects of the technology on health outcomes.
Whole Exome Sequencing **Whole Genome Sequencing** (EXaCT-1, ExomeNext, ExomeNext-Rapid, TruGenome tests, XomeDx)	Standard whole exome sequencing, with trio testing (testing of child and both parents) when possible, **meets the definition of medical necessity** for the evaluation of unexplained congenital or neurodevelopmental disorder in children when **ALL** of the following criteria are met: • The member has been evaluated by a clinician with expertise in clinical genetics, including at minimum a family history and phenotype description, and counseled about the potential risks of genetic testing • There is potential for a change in management and clinical outcome for the member being tested • A genetic etiology is considered the most likely explanation for the phenotype despite previous genetic testing (eg, chromosomal microarray analysis and/or targeted single-gene testing), **OR** when previous genetic testing has failed to yield a diagnosis and the affected member is faced with invasive procedures or testing as the next diagnostic step (eg, muscle biopsy). Rapid whole exome sequencing or rapid whole genome sequencing, with trio testing when possible, **meets the definition of medical necessity** for the evaluation of critically ill infants in neonatal or pediatric intensive care with a suspected genetic disorder of unknown etiology when **both (1 & 2)** of the following criteria are met: 1. **At least one** of the following criteria is met: a. Multiple congenital anomalies (e.g. persistent seizures, abnormal ECG, hypotonia); b. An abnormal laboratory test or clinical features suggests

	a genetic disease or complex metabolic phenotype (e.g, abnormal newborn screen, hyperammonemia, lactic acidosis not due to poor perfusion); **or** c. An abnormal response to standard therapy for a major underlying condition. 2. **None** of the following criteria apply regarding the reason for admission to intensive care: a. An infection with normal response to therapy; b. Isolated prematurity; c. Isolated unconjugated hyperbilirubinemia; d. Hypoxic Ischemic Encephalopathy; e. Confirmed genetic diagnosis explains illness; f. Isolated Transient Neonatal Tachypnea; g. Nonviable neonates. Whole exome sequencing is considered **experimental or investigational** for the diagnosis of genetic disorders in all other situations. The evidence is insufficient to determine the effects of the technology on health outcomes. Whole genome sequencing is considered **experimental or investigational** for the diagnosis of genetic disorders in all other situations. The evidence is insufficient to determine the effects of the technology on health outcomes. Whole exome sequencing and whole genome sequencing are considered **experimental or investigational** for screening for genetic disorders. The evidence is insufficient to determine the effects of the technology on health outcomes.
X Chromosome Abnormality Test (XCAT) for Turner Syndrome (XCAT-TS)	The use of the XCAT-TS test to detect Classic and Mosaic Turner Syndrome is considered **experimental or investigational** as there is insufficient clinical evidence in peer-reviewed literature to permit conclusions the test is as beneficial as the established alternatives and on net health outcomes

*Diagnostic Scoring System for LQTS

Criteria	Points
Electrocardiographic findings	

* QTc >480 msec	3
* QTc 460-470 msec	2
* QTc <450 msec	1
History of torsades de pointes	2
T-wave alternans	1
Notched T-waves in three leads	1
Low heart rate for age	0.5
Clinical history	
* Syncope brought on by stress	2
* Syncope without stress	1
* Congenital deafness	0.5
Family history	
* Family members with definite LQTS	1
* Unexplained sudden death in immediate family members younger than 30 years of age	0.5

Genetic Counseling: Genetic counseling is covered in accordance to the member's contract benefits for medical counseling. Pre and post genetic counseling **meets the definition of medical necessity** as an adjunct to the genetic test(s).

Genetic testing is considered **experimental or investigational**, as there is insufficient clinical evidence to support the use of genetic testing for screening the general population including genetic disease screening panels, as well as large comprehensive carrier screening panels (e.g. Counsyl Universal Carrier Genetic test, GoodStart Select, InheriGen™, Inheritest™, Natera One™ Disease Panel, Natera Horizon). There is a lack of clinical data to permit conclusions on net health outcomes.

Home testing (including self-testing home kits) is considered **experimental or investigational** as the clinical validity of the tests have not been established. The evidence is insufficient to determine the effects of the technology on health outcomes.

The following tests are considered **experimental or investigational**, as there is insufficient evidence to support the use of these tests for all indications. Although there are ongoing clinical studies the current data are inadequate to permit scientific conclusions on net health outcomes:

- Cancer Gene Mutation Panel
- Cancer Somatic Mutation Panel
- CardioPredict™
- ColonSentry®
- DetoxiGenomic® Profile Test
- epiSEEK™
- GenArray™
- Gene Trails Genotyping Panels
- GeneSeq®:Cardio
- Genoptix® MDS Molecular Profile
- HCM Sequencing Panel

- Heart Cholesterol Balance™
- Heart HDL Map™
- Heredi-T™ Cystic Fibrosis
- Leigh's Disease Panel
- MD Tox Cardiac & Risk Factors Profile
- Mitochondrial Disorders Panel
- MitoMED-Autism™
- Monogenic Hypertension Evaluation Panel
- mtSEEK®
- MVL Vision Panel
- Nemaline Myopathy Test Panel
- NeoTYPE™ AML Reflex Panel
- NeoTYPE™ MDS/CMML Panel
- nucSEEK™
- Oncogene Panel Mutation Analysis for Solid Tumor
- OncoPlex Multiplexed Gene Sequencing Panel
- OneOme RightMed Pharmacogenomic Test
- Pan Cardiomyopathy Panel
- PancNext™
- Panexia™
- Periodic Fever Syndromes Panel
- RenalNext™
- Reprogenetics CGH Test Panels
- RetnaGene™ AMD
- Spinocerebellar Ataxia Panel
- ToxLok
- ToxProtect
- TransPredict FCGR3A
- Vascular Aneurysm Genetic Panel
- Vita Risk®
- X-linked Intellectual Disability Panel.

CYTOGENETIC STUDIES (CHROMOSOMAL STUDIES)

NOTE: Coverage for cytogenetic studies and counseling are applicable only under those contracts that include benefits for cytogenetic testing, genetic testing, preventive health services, screening services, and medical counseling.

Cytogenetic studies **meet the definition of medical necessity** for the diagnosis and treatment of the following conditions (the list is not all-inclusive):

- Genetic disorders (e.g., Down's Syndrome) in a fetus
- Failure of sexual development
- Chronic myelogenous leukemia
- Acute leukemias lymphoid, acute leukemias myeloid
- Acute leukemias unclassified; **or**
- Myelodysplasia.

BILLING/CODING INFORMATION:

CPT Coding:

81161	DMD (dystrophin) (e.g., Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed
81170	ABL1 (ABL proto-oncogene 1, nonreceptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain
81171	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
81172	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)
81173	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence
81174	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant
81200	ASPA (aspartoacylase) (e.g. Canavan disease) gene analysis, common variants (e.g. E285A, Y231X)
81204	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)
81205	BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (e.g. Maple syrup urine disease) gene analysis, common variants (e.g. R183P, G278S, E422X)
81209	BLM (Bloom syndrome, RecQ helicase-like) (e.g. Bloom syndrome) gene analysis, 2281del6ins7 variant
81218	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence
81219	CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9
81220	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g. cystic fibrosis) gene analysis; common variants (e.g. ACMG/ACOG guidelines)
81221	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g. cystic fibrosis) gene analysis; known familial variants
81222	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g. cystic fibrosis) gene analysis; duplication/deletion variants
81223	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g. cystic fibrosis) gene analysis; full gene sequence

81224	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g. cystic fibrosis) gene analysis; intron 8 poly-T analysis (e.g. male infertility)
81225	CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (e.g. drug metabolism), gene analysis, common variants (e.g. *2, *3, *4, *8, *17) **(Investigational)**
81226	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g. drug metabolism), gene analysis, common variants (e.g. *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)
81227	CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (e.g. drug metabolism), gene analysis, common variants (e.g. *2, *3, *5, *6) **(Investigational)**
81228	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (e.g. Bacterial Artificial Chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)
81229	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities
81230	CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *22) **(Investigational)**
81231	CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism) gene analysis, common variants (eg, *2, *3, *4, *5 *6, *7) **(Investigational)**
81232	DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism) gene analysis, common variant(s) (eg, *2A, *4, *5, *6) **(Investigational)**
81238	F9 (coagulation factor IX) (eg, hemophilia B) full gene sequence **(Investigational)**
81240	F2 (prothrombin, coagulation factor II) (e.g. hereditary hypercoagulability) gene analysis, 20210G>A variant **(Investigational)**
81241	F5 (coagulation Factor V) (e.g. hereditary hypercoagulability) gene analysis, Leiden variant **(Investigational)**
81242	FANCC (Fanconi anemia, complementation group C) (e.g. Fanconi anemia, type C) gene analysis, common variant (e.g. IVS4+4A>T)
81243	FMR1 (Fragile X mental retardation 1) (e.g. fragile X mental retardation) gene analysis; evaluation to detect abnormal (e.g. expanded) alleles
81244	FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis;characterization of alleles (eg, expanded size and promoter methylation status)
81245	FLT3 (fms-related tyrosine kinase 3) (e.g. acute myeloid leukemia), gene analysis, internal tandem duplication (ITD) variants (ie, exons 14, 15)
81246	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836) **(Investigational)**
81250	G6PC (glucose-6-phosphatase, catalytic subunit) (e.g. Glycogen storage disease, Type 1a, von Gierke disease) gene analysis, common variants (e.g. R83C, Q347X)
81251	GBA (glucosidase, beta, acid) (e.g. Gaucher disease) gene analysis, common variants (e.g. N370S, 84GG, L444P, IVS2+1G>A)
81255	HEXA (hexosaminidase A [alpha polypeptide]) (e.g. Tay-Sachs disease) gene analysis, common variants (e.g. 1278insTATC, 1421+1G>C, G269S)
81256	HFE (hemochromatosis) (e.g. hereditary hemochromatosis) gene analysis, common variants (e.g. C282Y, H63D)
81257	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g. alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis, for common deletions or variant (e.g. Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, Constant Spring)

81258	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant
81259	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequence
81260	IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (e.g. familial dysautonomia) gene analysis, common variants (e.g. 2507+6T>C, R696P)
81265	Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (e.g. pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [e.g. buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells) **(Investigational)**
81266	Comparative analysis using Short Tandem Repeat (STR) markers; each additional specimen (e.g. additional cord blood donor, additional fetal samples from different cultures, or additional zygosity in multiple birth pregnancies) (List separately in addition to code for primary procedure) **(Investigational)**
81269	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variants
81277	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities
81287	MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme) promoter methylation analysis
81290	MCOLN1 (mucolipin 1) (e.g. Mucolipidosis, type IV) gene analysis, common variants (e.g. IVS3-2A>G, del6.4kb)
81291	MTHFR (5,10-methylenetetrahydrofolate reductase) (e.g. hereditary hypercoagulability) gene analysis, common variants (e.g. 677T, 1298C) **(Investigational)**
81302	MECP2 (methyl CpG binding protein 2) (e.g. Rett syndrome) gene analysis; full sequence analysis
81303	MECP2 (methyl CpG binding protein 2) (e.g. Rett syndrome) gene analysis; known familial variant
81304	MECP2 (methyl CpG binding protein 2) (e.g. Rett syndrome) gene analysis; duplication/deletion variants
81307	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence
81308	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant
81310	NPM1 (nucleophosmin) (e.g. acute myeloid leukemia) gene analysis, exon 12 variants
81313	PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (eg, prostate cancer) **(Investigational)**
81321	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis
81322	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant
81323	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant
81324	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis
81325	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with

	liability to pressure palsies) gene analysis; full sequence analysis
81326	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant
81328	SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction) gene analysis, common variant(s) (eg, *5) **(Investigational)**
81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (e.g. Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
81332	SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (e.g. alpha-1-antitrypsin deficiency), gene analysis, common variants (e.g. *S and *Z)
81334	RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy) gene analysis, targeted sequence analysis (eg, exons 3-8) **(Investigational)**
81346	TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism) gene analysis, common variant(s) (eg, tandem repeat variant) **(Investigational)**
81350	UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, drug metabolism, hereditary unconjugated hyperbilirubinemia [Gilbert syndrome]) gene analysis, common variants (eg, *28, *36, *37) **(Investigational)**
81355	VKORC1 (vitamin K epoxide reductase complex, subunit 1) (e.g. warfarin metabolism), gene analysis, common variants (e.g. -1639G>A, c.173+1000C>T) **(Investigational)**
81370	HLA Class I and II typing, low resolution (e.g. antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and DQB1
81371	HLA Class I and II typing, low resolution (e.g. antigen equivalents); HLA-A, -B, and DRB1 (e.g. verification typing)
81372	HLA Class I typing, low resolution (e.g. antigen equivalents); complete (ie, HLA-A, -B, and C)
81373	HLA Class I typing, low resolution (e.g. antigen equivalents); 1 locus (e.g. HLA-A, -B, or C), each
81374	HLA Class I typing, low resolution (e.g. antigen equivalents); 1 antigen equivalent (e.g. B*27), each
81375	HLA Class II typing, low resolution (e.g. antigen equivalents); HLA-DRB1/3/4/5 and DQB1
81376	HLA Class II typing, low resolution (e.g. antigen equivalents); 1 locus (e.g. HLA-DRB1, DRB3/4/5, -DQB1, -DQA1, -DPB1, or DPA1), each
81377	HLA Class II typing, low resolution (e.g. antigen equivalents); 1 antigen equivalent, each
81378	HLA Class I and II typing, high resolution (ie, alleles or allele groups), HLA-A, -B, -C, and DRB1
81379	HLA Class I typing, high resolution (ie, alleles or allele groups); complete (ie, HLA-A, -B, and C)
81380	HLA Class I typing, high resolution (ie, alleles or allele groups); 1 locus (e.g. HLA-A, -B, or C), each
81381	HLA Class I typing, high resolution (ie, alleles or allele groups); 1 allele or allele group (e.g. B*57:01P), each
81382	HLA Class II typing, high resolution (ie, alleles or allele groups); 1 locus (e.g. HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQB1, -DQA1, -DPB1, or DPA1), each
81383	HLA Class II typing, high resolution (ie, alleles or allele groups); 1 allele or allele group (e.g. HLA-DQB1*06:02P), each
81400	Molecular pathology procedure, Level 1 (e.g. identification of single germline variant [e.g. SNP] by techniques such as restriction enzyme digestion or melt curve analysis)
81401	Molecular pathology procedure, Level 2 (e.g. 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic

	mutation disorder/triplet repeat)
81402	Molecular pathology procedure, Level 3 (e.g., > 10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD])
81403	Molecular pathology procedure, Level 4 (e.g. analysis of single exon by DNA sequence analysis, analysis of > 10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)
81404	Molecular pathology procedure, Level 5 (e.g. analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)
81405	Molecular pathology procedure, Level 6 (e.g. analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)
81406	Molecular pathology procedure, Level 7 (e.g. analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)
81407	Molecular pathology procedure, Level 8 (e.g. analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of > 50 exons, sequence analysis of multiple genes on one platform)
81408	Molecular pathology procedure, Level 9 (e.g. analysis of > 50 exons in a single gene by DNA sequence analysis)
81410	Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK **(Investigational)**
81411	Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); duplication/deletion analysis, panel must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1 **(Investigational)**
81412	Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1 **(Investigational)**
81413	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A)
81414	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1
81415	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
81416	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)
81417	Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)

81425	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
81426	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)
81427	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)
81431	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes **(Investigational)**
81432	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53 **(Investigational)**
81433	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11 **(investigational)**
81434	Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A **(Investigational)**
81435	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); genomic sequence analysis panel, must include sequencing of at least 10 genes, including APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PTEN, SMAD4, and STK11 **(Investigational)**
81436	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); duplication/deletion analysis panel, must include analysis of at least 5 genes, including MLH1, MSH2, EPCAM, SMAD4 **(Investigational)**
81437	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL **(Investigational)**
81438	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL **(Investigational)**
81439	Hereditary cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), genomic sequence analysis panel, must include sequencing of at least 5 cardiomyopathy-related genes (eg, DSG2, MYBPC3, MYH7, PKP2, TTN)
81440	Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP **(Investigational)**
81442	Noonan spectrum disorders (eg, Noonan syndrome, cardio-faci—cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS,

	KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1 **(Investigational)**
81443	Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH) **(Investigational)**
81448	Hereditary peripheral neuropathies panel (eg, Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (eg, BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, and SPTLC1) **(Investigational)**
81460	Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and retinitis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection **(Investigational)**
81465	Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed **(Investigational)**
81470	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1,OCRL, RPS6KA3,and SLC16A2 **(Investigational)**
81471	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM,MECP2,MED12,MID1,OCRL, RPS6KA3,and SLC16A2 **(Investigational)**
81493	Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score **(investigational)**
81539	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score **(Investigational)**
81541	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a disease-specific mortality risk score **(Investigational)**
81542	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score (**Investigational**)
81551	Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy **(Investigational)**
83080	Hemosiderin; b-Hexosaminidase, each assay
88230	Tissue culture for non-neoplastic disorders; lymphocyte
88233	Tissue culture for non-neoplastic disorders; skin or other solid tissue biopsy
88235	Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells
88237	Tissue culture for neoplastic disorders; bone marrow, blood cells

88239	Tissue culture for neoplastic disorders; solid tumor
88240	Cryopreservation, freezing and storage of cells, each cell line
88241	Thawing and expansion of frozen cells, each aliquot
88245	Chromosome analysis for breakage syndromes; baseline Sister Chromatid Exchange (SCE), 20-25 cells
88248	Chromosome analysis for breakage syndromes; baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes (eg, for ataxia telangiectasia, Fanconi anemia, fragile X)
88249	Chromosome analysis for breakage syndromes; score 100 cells, clastogen stress (eg, diepoxybutane, mitomycin C, ionizing radiation, UV radiation)
88261	Chromosome analysis; count 5 cells, 1 karyotype, with banding
88262	Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding
88263	Chromosome analysis; count 45 cells for mosaicism, 2 karyotypes, with banding
88264	Chromosome analysis; analyze 20-25 cells
88267	Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells, 1 karyotype, with banding
88269	Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding
88271	Molecular cytogenetics; DNA probe, each (e.g., FISH-fluorescence in situ hybridization)
88272	Chromosomal in situ hybridization, analyze 3 – 5 cells (e.g., for derivatives and markers)
88273	Chromosomal in situ hybridization, analyze 10 – 30 cells (e.g., for microdeletions)
88274	Interphase in situ hybridization, analyze 25 – 99 cells
88275	Interphase in situ hybridization, analyze 100 – 300 cells
88280	Chromosome analysis; additional karyotypes, each study
88283	Chromosome analysis; additional specialized banding technique (eg, NOR, C-banding)
88285	Chromosome analysis; additional cells counted, each study
88289	Chromosome analysis; additional high resolution study
88291	Cytogenetics and molecular cytogenetics, interpretation and report
96040	Medical genetics and genetic counseling services, each 30 minutes face-to-face with patient/family
0004M	Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score **(Investigational)**
0005U	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score **(Investigational)**
0007U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service **(Investigational)**
0008U	Helicobacter pylori detection and antibiotic resistance, DNA, 16S and 23S rRNA, gyrA, pbp1, rdxA and rpoB, next generation sequencing, formalin-fixed paraffin embedded or fresh tissue or fecal sample, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin **(Investigational)**
0011M	Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and/or urine, algorithms to predict high-grade prostate cancer risk **(Investigational)**
0012U	Germline disorders, gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood, report of specific gene rearrangement(s) **(Investigational)**
0017U	Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or

	detected
0021U	Oncology (prostate), detection of 8 autoantibodies (ARF 6, NKX3-1, 5'-UTR-BMI1, CEP 164, 3'-UTR-Ropporin, Desmocollin, AURKAIP-1, CSNK2A2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score **(Investigational)**
0023U	Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3 mutation and indication for or against the use of midostaurin
0027U	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15
0029U	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823) **(Investigational)**
0030U	Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823) **(Investigational)**
0031U	CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7) **(Investigational)**
0032U	COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant **(Investigational)**
0033U	HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G]) **(Investigational)**
0034U	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism), gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5) **(Investigational)**
0036U	Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses
0046U	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative **(Investigational)**
0047U	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score **(Investigational)**
0049U	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative **(Investigational)**
0050U	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements **(Investigational)**
0053U	Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade **(Investigational)**
0063U	Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder **(Investigational)**
0069U	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score **(Investigational)**
0070U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN) **(Investigational)**

0071U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure) **(Investigational)**
0072U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure) **(Investigational)**
0073U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure) **(Investigational)**
0074U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure) **(Investigational)**
0075U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5' gene duplication/multiplication) (List separately in addition to code for primary procedure) **(Investigational)**
0076U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3' gene duplication/ multiplication) (List separately in addition to code for primary procedure) **(Investigational)**
0078U	Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder **(Investigational)**
0079U	Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification **(Investigational)**
0094U	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis
0113U	Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score **(Investigational)**
0117U	Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain **(Investigational)**
0129U	Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53) **(Investigational)**
0130U	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure) **(Investigational)**
0131U	Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure) **(Investigational)**
0132U	Hereditary ovarian cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes)

	(List separately in addition to code for primary procedure) **(Investigational)**
0133U	Hereditary prostate cancer–related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure) **(Investigational)**
0134U	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure) **(Investigational)**
0135U	Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure) **(Investigational)**
0136U	ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) *mRNA sequence analysis* (List separately in addition to code for primary procedure) **(Investigational)**
0137U	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) *mRNA sequence analysis* (List separately in addition to code for primary procedure) **(Investigational)**
0138U	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) **(Investigational)**
0156U	Copy number (eg, intellectual disability, dysmorphology), sequence analysis (**Investigational**)
0157U	APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure) (**Investigational**)
0158U	MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) (**Investigational**)
0159U	MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) (**Investigational**)
0160U	MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) (**Investigational**)
0161U	PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary nonpolyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure) (**Investigational**)
0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure) (**Investigational**)
0170U	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis **(Investigational)**
0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence **(Investigational)**
0173U	Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes (**Investigational**)
0175U	Psychiatry (eg, depression, anxiety); genomic analysis panel, variant analysis of 15 genes (**Investigational**)

HCPCS Coding:

G9143	Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s) **(Investigational)**
S0265	Genetic counseling, under physician supervision, each 15 minutes
S3722	Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil **(Investigational)**
S3840	DNA analysis for germline mutations of the RET Proto-Oncogene for susceptibility to multiple endocrine neoplasia Type 2
S3841	Genetic testing for retinoblastoma
S3842	Genetic testing for Von Hippel-Lindau Disease
S3844	DNA analysis of the Connexin 26 Gene (GJB2) for susceptibility to congenital, profound, deafness
S3845	Genetic testing for Alpha-Thalassemia
S3846	Genetic testing for Hemoglobin E Beta-Thalassemia
S3849	Genetic testing for Niemann-Pick Disease
S3850	Genetic testing for sickle cell anemia
S3852	DNA analysis for APOE epsilon 4 allele for susceptibility to Alzheimer's disease **(Investigational)**
S3853	Genetic testing for myotonic muscular dystrophy
S3861	Genetic testing, sodium channel, voltage-gated, type V, alpha subunit (SCN5A) and variants for suspected Brugada Syndrome
S3865	Comprehensive gene sequence analysis for hypertrophic cardiomyopathy
S3866	Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (HCM) in an individual with a known HCM mutation in the family
S3870	Comparative genomic hybridization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability

REIMBURSEMENT INFORMATION:

Florida Blue has adopted the U.S. Preventive Services Task Force (USPSTF) Recommendations. In order to be covered, Services shall be provided in accordance with prevailing medical standards consistent with the USPSTF Recommendations.

Codes 83080, 88230, 88233, 88235, 88237, 88239, 88240, 88241, 88245, 88248, 88249, 88261, 88262, 88263, 88264, 88267, 88269 are limited to four (4) tests within a 12-month period.

Code 88291 is limited to twenty-five (25) of each test within a 12-month period.

Code 88271 is limited to forty-one (41) tests within a 12-month period.

Code 88280 is limited to two (2) tests within a 12-month period.

Codes 88272, 88273, 88274, 88283, 88285, 88289, S3841, S3842, S3844, S3845, S3846, S3849, S3850, S3853 and S3861 are limited to one (1) of each test within a 12-month period.

The following information is required for services subject to medical review, including services in excess of reimbursement limitations: documentation to support medical necessity: reason for test(s), previous lab results, how the results of the test will be utilized, how the results of the test will contribute to improved health outcomes, or alters patient's treatment and or management.

LOINC Codes:

Documentation Table	LOINC Codes	LOINC Time Frame Modifier Code	LOINC Time Frame Modifier Codes Narrative
Physician history and physical	28626-0	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Attending physician visit note	18733-6	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Attending physician progress note	18741-9	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Plan of treatment	18776-5	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Laboratory studies	26436-6	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products:

The following National Coverage Determinations (NCDs) were reviewed on the last guideline reviewed date and are located at cms.gov: Next Generation Sequencing (NGS) (90.2), Pharmacogenomic Testing for Warfarin Response (90.1) and Cytogenetic Studies (190.3).

The following were reviewed on the last guideline reviewed date: MolDX LCDs located at palmettogba.com.

The following Local Coverage Determination (LCD) located at www.fcso.com was reviewed on the last guideline reviewed date:Noncovered Services (L33777).

DEFINITIONS:

None applicable.

RELATED GUIDELINES:

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer, 05-86000-26
Genetic Testing for Hereditary Breast or Ovarian Cancer, 05-82000-30
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes , 05-82000-31
Tumor/Genetic Markers, 05-86000-22

OTHER:

None applicable.

REFERENCES:

1. Ackerman MJ, Priori SG, Willems S et al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8(8):1308-39.
2. Adaptive Biotechnologies. clonoSEQ® Assay Technical Summary; September 2018.
3. American Association of Clinical Urologists, Inc. (AACU). Position Statement: Genomic Testing in Prostate Cancer; accessed at aacuweb.org 11/12/18.
4. American College of Medical Genetics and Genomics (ACMG) Board of Directors. Points to consider for informed consent for genome/exome sequencing. Genet Med, 15 (9), 748-9 Sep 2013.
5. American College of Medical Genetics and Genomics (ACMG) Practice Guidelines; accessed at acmg.net.
6. American College of Obstetricians and Gynecologists (ACOG) Clinical Guidelines; accessed at acog.org.
7. American Society of Clinical Oncology (ASCO). Clinical Guidelines; accessed at asco.org.
8. American Urological Association (AUA). Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. 2017; accessed at auanet.org.
9. American Urological Association (AUA). Early Detection of Prostate Cancer (2018); accessed at auanet.org.
10. Ashley EA, Hershberger RE, Caleshu C et al. Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation 2012; 126(1):142-57.
11. Bejar RL, Ebert BL, Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes, J Clin Oncol 2011; 29:504-515.
12. Bejar RL, Stevenson K, et al, Clinical Effect of Point Mutations in Myelodysplastic Syndromes, N Engl J Med 2011;364:2496-506.
13. Bekelman JE, Rumble RB, et al. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an AUA/ASTRO/SUO Guideline Summary. J Oncol Pract. 2018 Oct;14(10):618-624.
14. Benitez J, Cool CL, et al. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Per Med 2018 Nov; 15(6):481-494.
15. BioReference Laboratories, Inc. 4Kscore® Test Dossier; 2019.
16. Blue Cross Blue Shield Association Evidence Positioning System® 2.02.28 Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy, 04/20.
17. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.10 - Identification of Microorganisms Using Nucleic Acid Probes, 03/20.
18. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.13 Genetic Testing for Alzheimer Disease, 05/20.
19. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.33 Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate, 12/19.
20. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.38 Cytochrome P450 Genotype-Guided Treatment Strategy, 07/19.

21. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.43 Genetic Testing for Cardiac Ion Channelopathies, 02/20.
22. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.44 Genetic Testing for Familial Cutaneous Malignant Melanoma, 04/20.
23. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.48 Genotype-Guided Warfarin Dosing, 07/19.
24. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.51 Genotype-Guided Tamoxifen Treatment, 08/19.
25. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies, 11/19.
26. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.63 Use of Common Genetic Variants (Single Nucleotide Variants) to Predict Risk of Nonfamilial Breast Cancer, 11/19.
27. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.67 KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy, 06/19.
28. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.68 Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients with Cancer, 04/20.
29. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.70 Genetic Testing for Lipoprotein (a) Variant(s) as a Decision Aid for Aspirin Treatment, 11/19.
30. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.72 Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart Disease, 04/20.
31. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.74 DNA-Based Testing for Adolescent Idiopathic Scoliosis, 02/20.
32. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.75 Genetic Testing of CADASIL Syndrome, 05/20.
33. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.83 Genetic Testing for FMR1 Variants (Including Fragile X Syndrome), 02/20.
34. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.86 Genetic Testing for Duchenne and Becker Muscular Dystrophy, 04/20.
35. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.81 Genetic Testing for Rett Syndrome, 06/20.
36. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.82 Genetic Testing for Inherited Thrombophilia, 06/20.
37. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.88 Genetic Testing for PTEN Hamartoma Tumor Syndrome, 03/20.
38. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.89 Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies, 02/20.
39. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.93 Genetic Cancer Susceptibility Panels Using Next Generation Sequencing, 11/19.
40. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.94 Genetic Testing for Lactase Insufficiency, 06/20.
41. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.95, Human Leukocyte Antigen (HLA) Testing for Celiac Disease, 12/19.
42. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.96 Genetic Testing for Statin-Induced Myopathy, 12/19.

43. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.99 Genetic Testing for Hereditary Pancreatitis, 03/20.

44. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.102 Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders, 04/20.

45. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.103 Genetic Testing for Macular Degeneration, 04/20.

46. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.104 Genetic Testing for α-Thalassemia, 07/19.

47. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.106 Genetic Testing for CHARGE Syndrome, 03/20.

48. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.107 Carrier Screening for Genetic Diseases, 09/19.

49. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.108 Fetal RHD Genotyping Using Maternal Plasma, 09/19.

50. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.110 Genetic Testing for Diagnosis and Management of Mental Health Conditions, 07/19.

51. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.111 Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management, 12/19.

52. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.114 Genetic Testing for Dilated Cardiomyopathy, 03/20.

53. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.116 Invasive Prenatal (Fetal) Diagnostic Testing, 09/19.

54. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.121 Miscellaneous Genetic and Molecular Diagnostic Tests, 08/19.

55. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.122 Chromosomal Microarray Analysis for the Evaluation of Pregnancy Loss, 09/19.

56. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia, 02/20.

57. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.126 Moderate Penetrance Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk, 08/19.

58. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.131 Pharmacogenetic Testing for Pain Management, 12/19.

59. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.137 Genetic Testing for Neurofibromatosis, 02/20.

60. Blue Cross Blue Shield Association Evidence Positioning System® 2.04.147 Next-Generation Sequencing for the Assessment of Measurable Residual Disease, 12/19.

61. Blue Cross Blue Shield Association Evidence Positioning System® 4.02.05 Preimplantation Genetic Testing, 09/19.

62. BlueCross BlueShield Association Technology Evaluation Center (TEC). Genetic testing for predisposition to inherited hypertrophic cardiomyopathy. 2009 TEC Assessments; Volume 24, Tab 11.

63. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). TEC Special Report: Array Comparative Genomic Hybridization (aCGH) for the Genetic Evaluation of Patients with Developmental Delay/Mental Retardation and Autism Spectrum Disorder. TEC Assessments 2009; Volume 24, Tab 10.

64. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Special Report: Chromosomal Microarray for the Genetic Evaluation of Patients With Global Developmental Delay, Intellectual Disability, and Autism Spectrum Disorder. TEC Assessments. 2015;30.

65. Bousman C, Maruf A, et al. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Curr Opin Psychiatry. 2019 Jan;32(1):7-15. doi: 10.1097/YCO.0000000000000465. PMID: 30299306.

66. Brand TC, Zhang N, Crager MR, et al. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-Gene Genomic Prostate Score. Urology. Mar 2016;89:69-75.

67. Cameron LD, Sherman KA, Marteau TM, Brown PM, Impact of Genetic Risk Information and Type of Disease on Perceived Risk, anticipated Affect, and Expected Consequences of Genetic Tests, Health Psychology, Vol 28(3), May 2009, 307-316.

68. Centers for Disease Control and Prevention (CDC), Genetic Testing; accessed at cdc.gov.

69. Centers for Medicare & Medicaid Services (CMS), National Coverage Determination (NCD) for Cytogenetic Studies (190.3); located at cms.gov.

70. Centers for Medicare & Medicaid Services (CMS), National Coverage Determination (NCD) for Next Generation Sequencing (NGS) (90.2); located at cms.gov.

71. Centers for Medicare & Medicaid Services (CMS), National Coverage Determination (NCD) for Pharmacogenomic Testing for Warfarin Response (90.1); located at cms.gov.

72. Chen RC, Rumble RB, et al, Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016 Jun 20;34(18):2182-90.

73. Christensen KD, Roberts JS, Whitehouse PJ, et al. Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease: a randomized trial. Ann Intern Med. Feb 02 2016;164(3):155-163.

74. Decipher Biosciences. Decipher Prostate Cancer Classifier Dossier, March 2020.

75. Decipher Biosciences. Decipher Prostate Cancer Classifier White Paper, May 2020.

76. Eggener SE, Rumble RB, et al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 May 1;38(13):1474-1494.

77. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendation: Use of Genomic Profiling to Assess Risk for Cardiovascular Disease (CVD) and Identify Individualized Prevention Strategies, 2010; accessed at egappreviews.org 06/25/13.

78. First Coast Service Options, Inc. (FCSO), Local Coverage Determination (LCD) for Noncovered Services (L33777), accessed at fcso.com.

79. Garcia-Closas M, Couch FJ, Lindstrom S et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013; 45(4):392-8.

80. Garlich, HM. Expanding Options in the Treatment of Prostate Cancer: The Impact of Prognostic Biomarkers on Patient Outcomes. Journal of Managed Care Medicine. 2020, Vol. 23 Issue 1, p49-53. 5p.

81. Genomic Health, Inc. Oncotype DX Genomic Prostate Score® Dossier, Oct. 2019.

82. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011.

83. Gittelman MC, Hertzman B, et al, PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013 Jul;190(1):64-9. Doi: 10.1016/j.juro.2013.02.018.

84. Gore JL, du Plessis M, et al. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol. 2020 Mar - Apr;10(2):e82-e90.

85. Greden JF, Parikh SV, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019 Apr;111:59-67.

86. Grosse SD, Rasmussen SA. Exome Sequencing: Value Is in the Eye of the Beholder. Genet Med, 22 (2), 280-282, Feb 2020.

87. Guerreiro R, Wojtas A, et al, TREM2 Variants in Alzheimer's Disease, N Engl J Med 2013;368:117-27.

88. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. Oct 13 2016;375(15):1415-1424.

89. Han C, Wang SM, et al. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):469-480. doi: 10.9758/cpn.2018.16.4.469. PMID: 30466219.

90. Herman L, Froelich J, et al, Utility of a Genomic-based, Personalized Medicine Test in Patients Presenting With Symptoms Suggesting Coronary Artery Disease, J Am Board Fam Med 2014;27:258 –267.

91. Hochheiser L, Juusola JL, et al, Economic Utility of a Blood-Based Genomic Test for the Assessment of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease, Popul Health Manag. 2014 Feb 25.

92. Holmes DR, Jr., Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA boxed warning: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. Jul 20 2010;56(4):321-341.

93. Hologic Health Economics: Medical Diagnostics Dossier for the PROGENSA® PCA3 Assay, March 2016.

94. Hu, JC, Tosoian JJ, et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. DOI:10.1200/PO.18.00163.JCO Precision Oncology - published online October 19, 2018.

95. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. Sep 2017;102(3):397-404.

96. Jonsson T, Stefansson H, et al, Variant of TREM2 Associated with the Risk of Alzheimer's Disease, N Engl J Med 2013;368:107-16.

97. Kalia SS, Adelman K, et al. Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics. Genet Med, 19 (2), 249-255 Feb 2017.

98. Kaul S, Wojno KJ, et al. Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using a Clinical Cell Cycle Risk Score, Per Med. 2019 Nov;16(6):491-499.

99. Konety B, Zappala SM, et al, The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices, Rev Urol. 2015;17(4):231-40.

100. Ladapo JA, Blecker S, et al, Clinical Implications of Referral Bias in the Diagnostic Performance of Exercise Testing for Coronary Artery Disease, J Am Heart Assoc. 2013 Dec 13;2(6):e000505.

101. Ladapo JA, Lyons H, et al, Enhanced Assessment of Chest Pain and Related Symptoms in the Primary Care Setting Through the Use of a Novel Personalized Medicine Genomic Test: Results From a Prospective Registry Study, Am J Med Qual. 2014 May 5.

102. Lansky A, Elashoff MR, Ng V et al. A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) trial. Am Heart J 2012; 164(3):320-6.

103. McPherson JA, Davis K, Yau M et al. The Clinical Utility of Gene Expression Testing on the Diagnostic Evaluation of Patients Presenting to the Cardiologist With Symptoms of Suspected Obstructive Coronary Artery Disease: Results From the IMPACT (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) Trial. Crit Pathw Cardiol 2013; 12(2):37-42.

104. MDxHealth Clinical Evidence Dossier: ConfirmMDX for Prostate Cancer, An Epigenetic Assay to Reduce Unnecessary Repeat Prostate Biopsies, 2018.

105. Macaluso M, Preskorn SH. Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing. J Psychiatr Pract. 2018 Nov;24(6):416-419. doi: 10.1097/PRA.0000000000000345. PMID: 30395549.

106. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med 2010; 12(11):742-5.

107. Marasio J, Spratt DE, et al. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2019 Nov 12.

108. MdxHealth Clinical Evidence Dossier, ConfirmMDx for Prostate Cancer, 2020.

109. Michelson DJ, Shevell MI, Sherr EH et al. Evidence Report: Genetic and metabolic testing on children with global developmental delay: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2011; 77(17):1629-35.

110. Miller DT, Adam MP, Aradhya S et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86(5):749-64.

111. Myriad Genetics Inc. GeneSight® Clinical Dossier, 12/19/18.

112. Myriad Genetics Inc. Prolaris® Prostate Cancer Clinical Dossier, April 2020.

113. Myriad Genetics Inc. Prolaris® Prostate Cancer White Paper, April 2020.

114. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology; located at nccn.org.

115. National Institute of Neurological Disorders and Stroke (NINDS), Peripheral Neuropathy Fact Sheet, last updated September 19, 2012; accessed at ninds.nih.gov 06/28/13.

116. Nurnberger J, Austin J, et al. What Should a Psychiatrist Know About Genetics? Review and Recommendations From the Residency Education Committee of the International Society of Psychiatric Genetics. J Clin Psychiatry. 2018 Nov 27;80(1).

117. Palmetto GBA: MolDX Local Coverage Determinations (LCDs) located at palmettogba.com.

118. Parekh DJ, Punnen S, et al, A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015 Sep;68(3):464-70. Doi: 10.1016/j.eururo.2014.10.021.

119. Pescini F, Nannucci S, Bertaccini B, et al. The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale: a screening tool to select patients for NOTCH3 gene analysis. Stroke. Nov 2012;43(11):2871-2876.

120. Robson ME, Storm CD, Weitzel J et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28(5):893-901.

121. Rosenblat JD, Lee Y, McIntyre, RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. J Affect Disord. 2018 Dec 1;241:484-491. doi: 10.1016/j.jad.2018.08.056. Epub 2018 Aug 14. PMID: 30149336.

122. Routhieaux M, Keels J, Tillery, EE. The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review. Ment Health Clin. 2018 Nov 1;8(6):294-302.

123. Sanda MG, Feng Z, Howard DH, et al. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA oncology. Aug 1 2017;3(8):1085-1093.

124. Solomon HV, Cates KW, Li KJ. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? Psychiatry Res. 2019 Jan;271:604-613. doi: 10.1016/j.psychres.2018.12.053. Epub 2018 Dec 8. PMID: 30554109.

125. Tanner JA, Davies PE, et al. Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists. J Psychiatr Res. 2018 Sep;104:157-162.

126. Thol F, Friesen I, et al, Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes, J Clin Oncol 2011; 29:2499-2506.

127. Thomas GS, Voros S, McPherson JA et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study. Circ Cardiovasc Genet 2013; 6(2):154-62.

128. Tonozzi TR, Braunstein GD, et al. Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study. Pharmacogenomics. 2018 Oct;19(15):1169-1179. doi: 10.2217/pgs-2018-0088. Epub 2018 Sep 12. PMID: 30207201.

129. U.S. Food and Drug Administration (FDA); accessed at fda.gov.

130. U.S Preventive Services Task Force (USPSTF), USPSTF Recommendations, accessed at: uspreventiveservicestaskforce.org.

131. Waterhouse RL, Jr., Van Neste L, Moses KA, et al. Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men. Urology. Apr 13 2018.

132. What are the Types of Genetic Tests? Library of Medicine (US). Genetics Home Reference; accessed at ghr.nlm.nih.gov.

133. White J, Shenoy BV, Tutrone RF, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate cancer and prostatic diseases. Apr 2018;21(1):78-84.

134. Zastrozhin MS, Sorokin AS, et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Hum Psychopharmacol. 2018 Nov;33(6):e2677. doi: 10.1002/hup.2677. Epub 2018 Oct 25. PMID: 30357930.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy & Coverage Committee on 12/05/19.

GUIDELINE UPDATE INFORMATION:

11/15/03	Medical Coverage Guideline Annual review. Developed separate guideline for Genetic Testing For Miscellaneous Diagnoses. Developed separate genetic testing guidelines for the following: BRCA1 and BRCA2, colon cancer (FAP and HNPCC), and medullary carcinoma of the thyroid (RET proto-oncogene).
01/01/04	Annual HCPCS coding update: added S3853.
07/01/05	HCPCS update: added S0265.
12/15/05	Biennial review: coverage unchanged.
01/01/06	Annual HCPCS coding update: added 83900, 83907, 83908, 83909, 83914; revised 83898, 83901.
06/15/06	Revision to include new codes into limitation section.
01/01/07	Annual HCPCS coding update: added 96040; deleted 99401, 99402, 99403, and 99404.
07/15/07	Annual review, coverage statements maintained, guideline reformatted, references updated.
01/01/08	Annual HCPCS coding update: revised 83898, 83900, 83901, and 83908.
01/01/09	Annual HCPCS coding update: descriptor revised for codes 83890, 83891, 83892, 83893, 83894, 83897, 83900, 83903, 83907, 83909, and 83914.
10/15/09	Annual review: position statement, reimbursement section, guideline title and references updated.
12/15/10	Revision; description section, inheritable disease diagnosis table reimbursement and coding sections updated; prenatal test table and Other Genetic Tests section added.
07/15/10	Revision; Other Genetic Tests section updated.
10/01/11	Revision; formatting changes.
11/15/11	Revision; CPT code 88275 removed from the Reimbursement Information section.
01/01/12	Annual HCPCS update. Added codes 81200-81408.
02/15/12	Revision; Postnatal and Other Genetic Tests section, Billing/Coding Information section and references updated.
04/01/12	Quarterly HCPCS update. Deleted codes S3835, S3837, S3843, S3847, S3848, S3851, S3860, S3862.
08/15/12	Revision; Postnatal and Other Genetic Tests section updated.
10/15/12	Revision; Postnatal and Other Genetic Tests, Coding, and references updated.
01/01/13	Annual HCPCS update: added codes 81161, 81252-81254, 81321-81326; revised codes 81400-81408; deleted codes 83890-83914; updated reimbursement section. Prenatal & Postnatal Genetic Tests sections and references updated.
05/15/13	Revision; Genetic Testing to Establish a Diagnosis of Inheritable Disease and Postnatal and Other Genetic Tests sections updated; coding and references updated.
07/01/13	Quarterly HCPCS update. Added code 0004M; revised codes 81400-81408; Program Exceptions section updated.
08/15/13	Revision; Postnatal and Other Genetic Tests, Program Exceptions, and references updated.
09/15/13	Revision; experimental test list and references updated.
11/15/13	Revision; Postnatal and Other Genetic Tests section and references updated.
01/01/14	Annual HCPCS update. Added code 81287; revised codes 81371, 81376, & S3870.
02/15/14	Revision; position statement section updated.
07/01/14	Quarterly HCPCS update. Revised codes 81402 & 81404.
08/15/14	Revision; position statement section and references updated.
10/15/14	Revision; Position statement section and references updated.

01/01/15	Annual HCPCS/CPT update. Added codes 81246, 81313, 81410-81471;deleted code S3855.
03/15/15	Revision; position statement section, coding, and references updated.
07/01/15	Quarterly CPT/HCPCS update. Revised codes 81401 and 81406.
10/15/15	Revision; position statement section and references updated.
10/26/15	Revision; investigational test list updated.
11/15/15	Revision; coding section updated.
12/15/15	Revision; position statement section, coding, program exception, and references updated.
01/01/16	Annual HCPCS/CPT update; codes 81170, 81218, 81219, 81272, 81273, 81311, 81314, 81412, 81432-81434, 81437, 81438, 81442, 81493 added; codes 81355, 81401-81404, 81435, 81436, 81445-81455 revised; code S3721 deleted.
02/15/16	Revision; position statement section updated.
04/01/16	Quarterly HCPCS/CPT update; code 0010M revised.
05/15/16	Revision; Position statement section, coding, and references updated.
08/08/16	Revision; experimental test list updated.
08/31/16	Revision; Position Statement section; experimental test list updated.
11/08/16	Revision; deleted code 81311.
12/15/16	Revision; Position statement section and references updated.
01/01/17	Annual CPT/HCPCS update. Added 81413, 81414, 81439, 81539; revised 81400-81408; deleted 81280-81282, 0010M.
02/15/17	Revision; position statement section and references updated.
04/15/17	Revision; FMR1 Mutations, Acute Myeloid Leukemia, CHARGE Syndrome, Neurofibromatosis, PTEN Hamartoma Tumor Syndrome, and Cytogenetic Studies position statements added; Hereditary Pancreatitis and Inherited Peripheral Neuropathy position statements updated; description, coding, and references updated.
05/01/17	CPT Code update: code 0005U added.
06/15/17	Revision; Position statement section updated including CADASIL Syndrome position statements added and genetic testing for Alzheimer Disease position statement revised; references updated.
08/01/17	Coding Updates: Added codes 0007U, 0008U, 0010U, 0012U-0017U.
10/15/17	Revision; CMA investigational position statement added for the evaluation of all other conditions of delayed development; Diagnosis Table, coding, and references updated.
11/15/17	Revision to AML position statement section.
12/15/17	Revision; position statement section updated including testing for one or more single nucleotide polymorphisms (SNPs) and references updated.
01/01/18	Annual CPT/HCPCS update. Added codes 81230-81232, 81238, 81258-81269, 81328, 81334, 81335, 81346, 81448, 81541, 81551, 0011M, 0027U-0034U; revised codes 81257, 81432, 81439; deleted code 0015U. Investigational test list updated and code 0020U added.
02/15/18	Revision; position statements, test names, and references updated.
04/01/18	Quarterly HCPCS/CPT update. Added codes 0036U, 0037U, 0040U.
05/15/18	Revision; position statements, coding, program exception, and references updated.
05/16/18	Revision; RPE65 genetic testing position statement added and investigational test list updated.
07/01/18	Quarterly HCPCS/CPT update. Added codes 0046U-0050U, 0053U.
09/15/18	Revision; investigational status maintained but statements updated for genotype-guided warfarin dosing and testing for diagnosis/management of mental health conditions; position

	statements added for CYP450 genotype-guided treatment strategy; NCCN breast cancer risk criteria for PALB2 testing updated.
10/01/18	Quarterly HCPCS/CPT update. Added codes 0063U, 0069U-0076U, 0078U, 0079U; deleted 0028U.
10/15/18	Coding updated.
12/15/18	Revision; Next generation sequencing for measurable residual disease investigational statement added; genetic and protein biomarkers for the diagnosis of prostate cancer test list updated; coding and references updated.
01/01/19	Annual CPT/HCPCS coding update. Added codes 81171-81174, 81204, 81443, 0081U; revised codes 81244, 81287, 0008U; deleted code 0020U.
02/15/19	Revision; code 0081U deleted (refer to MCG 05-86000-22).
03/15/19	Revision; Position statements for FMR1 variants testing and FLT3, NPM1, and CEBPA variants testing updated; coding and references updated.
05/15/19	Revision; Position statements, including testing for dilated cardiomyopathy, and references updated.
07/01/19	Quarterly CPT/HCPCS update. Added codes 0094U, 0101U-0104U.
08/15/19	Revision; Genetic testing panels for mental health disorders & genetic testing for diagnosis and management of mental health disorders position statements maintained; testing for Rhett syndrome position statements and references updated.
10/01/19	Quarterly CPT/HCPCS update. Added codes 0113U, 0117U, 0129U-0138U; deleted code 0104U. Deleted codes 81206-81208, 0016U.
10/24/19	Revision; PALB2 testing section updated.
01/01/20	Review; Assessment of MRD statements updated; statements for assays & gene expression profiling for diagnosis, cancer risk assessment, or management of prostate cancer maintained; coding & references updated.Removed codes 0013U, 0014U, 0048U, 0056U, 0101U-0103U (refer to MCG 5-86000-22).Annual CPT/HCPCS coding update. Added codes 81277, 81307, 81308, 81542, 0156U-0162U; revised code 81350.
04/01/20	Quarterly CPT/HCPCS update. Added codes 0170U & 0171U.
05/15/20	Revision; Whole exome and whole genome position statements updated; coding, and references updated.
07/01/20	Revision: CADASIL syndrome positon statements updated; gene expression analysis and protein biomarkers to guide management of prostate cancer reviewed and position statement maintained; references updated. Quarterly CPT/HCPCS update. Added codes 0173U and 0175U.